GSK PLC SP. ADR/2 NEW Cash Flow Conversion Efficiency

Latest as of June 2026: 0.157x

GSK PLC SP. ADR/2 NEW cash flow conversion efficiency. Based on the latest financial reports, GSK PLC SP. ADR/2 NEW (GS70) has a cash flow conversion efficiency ratio of 0.157x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.69 Billion ≈ $3.14 Billion USD) by net assets (€17.18 Billion ≈ $20.08 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of GSK PLC SP. ADR/2 NEW (2021–2025)

Cash flow conversion efficiency of GSK PLC SP. ADR/2 NEW from 2021 to 2025. This chart illustrates how GSK PLC SP. ADR/2 NEW's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GS70 live share price for real-time trading data and today's change.

GSK PLC SP. ADR/2 NEW Cash Flow Conversion Ratio Explained

GSK PLC SP. ADR/2 NEW cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

GSK PLC SP. ADR/2 NEW Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GSK PLC SP. ADR/2 NEW ranked by their cash flow conversion efficiency. Also see GS70 market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
McKesson Corporation NYSE:MCK	0.057x
UBS Group AG SW:UBSG	-0.043x
CME Group Inc NASDAQ:CME	0.047x
Pinduoduo Inc F:9PDA	0.039x
Air Liquide SA PA:AI	0.130x
CVS Health Corp NYSE:CVS	0.045x
Grupo México S.A.B. de C.V MX:GMEXICOB	0.129x
General Dynamics Corporation NYSE:GD	0.070x

Annual Cash Flow Conversion Efficiency for GSK PLC SP. ADR/2 NEW (2021–2025)

The table below shows the annual cash flow conversion efficiency of GSK PLC SP. ADR/2 NEW from 2021 to 2025. Review GSK PLC SP. ADR/2 NEW free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€15.96 Billion ≈ $18.65 Billion	€7.74 Billion ≈ $9.05 Billion	0.485x	-3.13%
2024-12-31	€13.09 Billion ≈ $15.30 Billion	€6.55 Billion ≈ $7.66 Billion	0.501x	-5.32%
2023-12-31	€12.79 Billion ≈ $14.96 Billion	€6.77 Billion ≈ $7.91 Billion	0.529x	-27.86%
2022-12-31	€10.10 Billion ≈ $11.80 Billion	€7.40 Billion ≈ $8.65 Billion	0.733x	+96.80%
2021-12-31	€21.34 Billion ≈ $24.95 Billion	€7.95 Billion ≈ $9.30 Billion	0.373x	--

About GSK PLC SP. ADR/2 NEW

F:GS70 Germany Drug Manufacturers - General

Market Cap

$110.73 Billion

€94.71 Billion EUR

Market Cap Rank

#249 Global

#49 in Germany

Share Price

€47.20

Change (1 day)

+0.00%

52-Week Range

€31.00 - €51.50

All Time High

€51.50